Biotechnology

Techseriesinsight > Blog > News > Biotechnology

May 8, 2025
PRNewswire
Biotechnology

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The presentations...

May 8, 2025
PRNewswire
Biotechnology

Ratio Therapeutics to Establish New Radiopharmaceutical Manufacturing Facility

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it entered into an agreement with the...

May 8, 2025
PRNewswire
Biotechnology

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase...

May 7, 2025
PRNewswire
Biotechnology

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) (“Sona”) announce today that they have entered into a Research Agreement (“Agreement”) to...

May 6, 2025
PRNewswire
Biotechnology

Factor Bioscience to Present Non-Viral Gene Editing and Cell Engineering Innovations at the ASGCT Annual Meeting

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation in the American Society of...

May 6, 2025
PRNewswire
Biotechnology

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has...

May 1, 2025
PRNewswire
Biotechnology

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the results of the Hepatitis B Perceptions and Insights Survey conducted by The Harris Poll, which...

May 1, 2025
PRNewswire
Biotechnology

Sapience Therapeutics Announces Oral Presentation at the Upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Featuring Lucicebtide Phase 2 Results

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced that data from...

April 29, 2025
PRNewswire
Biotechnology

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced that, effective April 20, 2025, the Board of Directors has appointed Sumant Ramachandra, M.D., Ph.D. as Chief...

April 29, 2025
PRNewswire
Biotechnology

Announcing Veeva AI

Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve...